贝伐单抗是一种单克隆抗血管内皮生长因子(VEGF)抗体,可结合并使所有VEGF亚型失活,从而防止血管生成,发展,和肿瘤的扩散。服用贝伐单抗后报告最多的副作用包括出血,高血压,心力衰竭,蛋白尿,血栓形成,和胃肠道穿孔。气胸很少被报道为贝伐单抗的并发症,但机制不清楚。本文旨在通过对该主题发表的当前病例报告的系统回顾,探讨使用贝伐单抗后气胸作为副作用的发生。使用PubMed进行了文献检索,谷歌学者,ScienceDirect,通过使用适当的关键字和开放访问目录,病例报告根据预定义的纳入和排除标准进行选择.我们的结果包括五个病例报告,进一步评估了人口学,临床,和治疗参数。这项系统评价得出的结论是,在含贝伐单抗的化疗后可能会发生气胸,尽管这种副作用相对罕见。意识到这种可能的副作用可以帮助临床医生在他们的实践中考虑气胸作为可能的鉴别诊断,当遇到在开始含有贝伐单抗的化疗后出现肺部症状的患者时;因此,及时诊断和治疗可以挽救生命。
Bevacizumab is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody that binds to and makes all of the VEGF isoforms inactive, and thus prevents angiogenesis, development, and the spread of the tumor. The most reported side effects after administering bevacizumab include bleeding, high blood pressure, heart failure, proteinuria, thrombosis, and gastrointestinal perforation. Pneumothorax has rarely been reported as a complication of bevacizumab, but with an unclear mechanism. This article aims to explore the occurrence of pneumothorax as a side effect after using bevacizumab through a systematic
review of current case reports published on the topic. A literature search was conducted using PubMed, Google Scholar, ScienceDirect, and Directory of Open Access through the utilization of appropriate keywords, and case reports were selected based on predefined inclusion and exclusion criteria. Our results encompass five case reports that were further evaluated for demographic, clinical, and treatment parameters. This systematic
review concludes that pneumothorax can occur after bevacizumab-containing chemotherapy although this side effect is relatively rare. Awareness regarding this possible side effect can assist clinicians during their practice in considering pneumothorax as a possible differential diagnosis when encountering patients presenting with pulmonary symptoms after starting bevacizumab-containing chemotherapy; hence, timely diagnosis and treatment can save a life.